Psoriatic arthritis: one year in review 2022 (original) (raw)
Related papers
One year in review 2018: psoriatic arthritis
2019
Spondyloarthritis (SpA) is an inflammatory condition characterised by a broad spectrum of clinical manifestations, laboratory abnormalities and imaging features that genetically tend to be associated with the major histocompatibility complex class 1 antigen, HLA-B27, and in which both peripheral and axial joints might be affected. In addition to arthritis, the typical musculoskeletal manifestations are enthesitis and dactylitis. Extraarticular manifestations such as acute anterior uveitis (AAU), psoriasis (PsO) and inflammatory bowel disease (IBD) are also typical of SpA. In this article we have reviewed the literature of the past year on one of the most important variants of SpA, i.e. psoriatic arthritis (PsA) (Medline search of articles published from 1st January 2018 to 31st January 2019).
Psoriatic Arthritis: an update on classification, clinical feature and therapies
Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease characterized by joint inflammation and cutaneous psoriasis. With advances in knowledge of genetics, immunohistology and pathogenesis, PsA is now recognized as a distinct disease entity. Unique clinical features include distal interphalangeal joint (DIPJ) involvement, dactylitis, enthesitis, axial involvement, specific radiographic features, and specific skin and nail changes. PsA affects young adults and is progressive and destructive, causing deformities, impaired physical function, reduced quality of life and lost of productivity. We now focus on more aggressive treatment in patients with progressive disease. With both conventional disease modifying anti-rheumatic drugs (DMARDs) and emerging biological agents, the outlook for patients with PsA has improved.
Psoriatic arthritis: An update on classification, clinical features and therapies
Psoriatic arthritis (PsA) is a chronic systemic inflammatory disease characterized by joint inflammation and cutaneous psoriasis. With advances in knowledge of genetics, immunohistology and pathogenesis, PsA is now recognized as a distinct disease entity. Unique clinical features include distal interphalangeal joint (DIPJ) involvement, dactylitis, enthesitis, axial involvement, specific radiographic features, and specific skin and nail changes. PsA affects young adults and is progressive and destructive, causing deformities, impaired physical function, reduced quality of life and lost of productivity. We now focus on more aggressive treatment in patients with progressive disease. With both conventional disease modifying anti-rheumatic drugs (DMARDs) and emerging biological agents, the outlook for patients with PsA has improved.
Annals of the Rheumatic Diseases, 2015
ObjectiveTo update the evidence on the efficacy and safety of pharmacological agents in psoriatic arthritis (PsA).MethodsSystematic literature review of randomised controlled trials comparing pharmacological interventions in PsA: non-steroidal anti-inflammatory drugs, glucocorticoid, synthetic disease modifying antirheumatic drugs (sDMARDs) either conventional or targeted, biologicals (bDMARDs), placebo or any combination. Main outcomes were American College of Rheumatology (ACR)20–50, Psoriasis Area Severity Index 75, radiographic progression, and withdrawals due to adverse events (AEs). Multiple studies of the same intervention were meta-analysed using random effects.ResultsIn total, 25 papers and 12 abstracts were included. The efficacy of tumour necrosis factor inhibitors (including the recently added golimumab and certolizumab pegol) was confirmed and 16 articles/abstracts focused on 3 drugs with new modes of action: ustekinumab (UST), secukinumab (SEC) and apremilast (APR). Al...
Psoriasis is a common disease in skin with the association of multiple conditions for coexistence. Psoriatic arthritis is the most prevalent condition of coexistence. Psoriatic Arthritis is observed among 30% of patients with psoriasis and it's characterized by a diverse clinical feature and hence it results in the delay of diagnosis and treatment. Initial reports on psoriatic arthritis emphasized the fact that a pattern observed in most patients, but at present it was identified that the patients suffering from psoriatic arthritis lose their quality of life due to impaired function of organs. In this review the focuses were on epidemiologic and pathophysiological characteristics of psoriatic arthritis to help clinicians to recognize the appropriate condition of psoriatic arthritis.
The Journal of Rheumatology
ObjectiveThe 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations provide an evidence-based guide for selecting therapy based on the individual's disease features. Beyond the disease features and associated conditions (eg, uveitis and inflammatory bowel disease), comorbidities play an important role in selecting therapy for an individual patient.MethodsWe performed a systematic literature review. We examined the available evidence to inform treatment selection based on the presence or absence of comorbidities in psoriatic arthritis (PsA).ResultsCommon comorbidities in PsA that may affect treatment selection include presence of baseline cardiovascular disease (CVD) or high risk for CVD, obesity and metabolic syndrome, liver disease, mood disorders, including depression in particular, chronic infections, malignancies, osteoporosis, and fibromyalgia and/or central sensitization.ConclusionComorbidities may influence both the ...
An update on pathogenesis of psoriatic arthritis and potential therapeutic targets
Expert Review of Clinical Immunology, 2019
Introduction: Innate immune response and bone remodeling are key factors contributing to the pathogenesis of psoriatic arthritis (PsA). Moreover, the evidence of autoantibodies in patients' sera suggests an autoimmune side in PsA. Besides the immune pathways, studies strongly support the role of genetic risk alleles in affecting the clinical heterogeneity of PsA as well as the response to therapy. A good clinical response to treatment, indeed, represents a challenge in PsA patients and the identification of patient-targeted therapies is still a critical issue. Areas covered: We performed a systematic review aiming at describing new evidence on PsA pathogenesis and treatments. Reported items for systematic reviews (PRISMA checklist) were analysed. Studies included from the PubMed database addressed the following items: innate immunity, autoimmunity, bone remodeling, and therapeutic targets in PsA; time frame of research 1970-2019. Specifically, we reviewed data on IL-17 inhibitors, abatacept, JAK inhibitors, ABT 122 and A (3) adenosine receptors agonist, CF101. Expert opinion: In PsA an intriguing pathogenetic network has been documented. Several biological and synthetic drugs are promising in terms of efficacy and safety profile.
Psoriatic arthritis – new perspectives
Archives of Medical Science
Psoriatic arthritis (PsA) is a seronegative arthropathy with many clinical manifestations, and it may affect nearly a half of patients with psoriasis. PsA should be diagnosed as early as possible to slow down joint damage and progression of disability. To improve the diagnosis of PsA, physicians should look for peripheral inflammatory pain, axial inflammatory pain, dactylitis, and buttock and sciatic pain. In most patients with PsA, pharmacologic treatment with non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and biologic agents is effective. However, when pharmacological treatment fails, patients with PsA may benefit from orthopedic surgery, which can improve both joint function and quality of life. Total hip arthroplasty, total knee arthroplasty, and arthroscopic synovectomy of the knee are the most common surgical procedures offered to patients with PsA. The management of PsA requires the care of a multidisciplinary team, which should include dermatologists, rheumatologists, physiotherapists, and orthopedic surgeons.
Clinical and experimental rheumatology, 2017
To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA). To create this new set of recommendations, the SIR "Spondyloartritis and Psoriatic Arthritis study group - A. Spadaro" went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations. An update on the available evidence on all of the biologics and new small molecules tested in PsA is reported, comprising the data for each of the individual articular manifestation. Indications for therapy inclusion criteria, choice of the drug, disease assessment, response definition, therapy failure management, and disease remission management for PsA peripheral joint arthritis, enthesitis, dactylitis, and spondyl...